.Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA07_AbiciparPegol.AbiciparPegol .Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA07_AbiciparPegol.AbiciparPegol| name: | AbiciparPegol |
| ATC code: | S01LA07 | route: | intravitreal |
| n-compartments | 2 |
Abicipar pegol is a designed ankyrin repeat protein (DARPin) that acts as a vascular endothelial growth factor A (VEGF-A) inhibitor. It was developed for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema by intravitreal injection. The drug showed prolonged intraocular half-life, allowing reduced injection frequency compared with existing anti-VEGF therapies. Despite positive efficacy results, abicipar pegol was not approved for clinical use due to safety concerns related to intraocular inflammation.
Pharmacokinetic parameters in adults with neovascular AMD following single-dose intravitreal administration.